

Amendment no. 1

Tender No.: - PMBI/DRUG/RC-175/2021

Dated: 11.01.2022

Subject: - Tender No. PMBI/DRUG/RC-175/2021 dated 23/12/2021 for supply of Drugs to Pharmaceuticals and Medical Devices Bureau of India (PMBI).

Reference: - Pre-Bid Meeting held on 31/12/2021 at 11:00 AM in the premises of PMBI.

Pharmaceuticals and Medical Devices Bureau of India (PMBI) has invited e-bids from the interested parties for “e- Tender for Supply Drugs for the year 2021- 2023”, vide Notice Inviting e-Tender No.- **PMBI/DRUG/RC-175/2021**. Detailed tender document containing eligibility criteria, selection mechanism, other terms and conditions are available on the website of Central Public Procurement Portal; www.eprocure.gov.in and PMBI Website; www.janaushadhi.gov.in.

After considering the suggestions/queries received from the prospective bidders on or before Pre-Bid meeting, the clarifications/amendments in respect to the tender document and specification of the tendered items have been made as per below as Part A, Part B respectively. All other technical specifications, terms, and conditions along with the tender schedule as mentioned in tender document shall remain unchanged.

The following amendment in Tender Document is hereby authorized: -

Part-A. (1)

Sl. No.	Tender Clause / Reference	Query / Suggestion	Clarification / Amendment
1.	Clause no. 3. J. ELIGIBILITY CRITERIA (TECHNICAL BID -COVER “A”):	Declaration for eligibility in participating the tender for quoted drugs in prescribed format as per Annexure-II.	Annexure II shall be on non-judicial Stamp Paper dully notarized as per clause 3. J.
2.	Atorvastatin Tablets IP 5mg (DC-2076). (Sl. No. 14, Column no. (3) Under “Annexure XII”)	One of bidder has requested to revise the deviation in strength of Atorvastatin Tablets IP 5mg (DC-2076) and composition of drug.	The strength of the Drug (DC-2076) is hereby amended as 5 mg.
3.	Divalproex Sodium Extended-Release Tablets IP 250 mg (DC-2104). (Sl. No. 42, Column no. (3) Under “Annexure XII”)	One of bidder has requested to revise the deviation in strength of Divalproex Sodium Extended-Release Tablets IP 250 mg (DC-2104) and composition of drug.	The strength of the Drug (DC-2104) is hereby amended as 250 mg.

4.	Atorvastatin 20mg, Aspirin 75mg and Clopidogrel 150mg Capsules (DC- 2075). (Sl. No. 13, Column no. (3) Under “Annexure XII”)	One of bidder has requested to revise the deviation in strength of Atorvastatin 20mg, Aspirin 75mg and Clopidogrel 150mg Capsules (DC- 2075) and composition of drug.	Tender conditions prevail.
5.	Dapagliflozin Tablets 5mg (DC-2101). (Sl. No. 39, Column no. (3) Under “Annexure XII”)	One of bidder has requested to amend the packaging type of this item from blister to Alu-Alu.	The packaging type is hereby amended as Alu-Alu instead of blister.
6.	Telmisartan 40mg, Cilnidipine 10mg and Chlorthalidone 12.5mg Tablets (DC-2137). (Sl. No. 75, Column no. (3) Under “Annexure XII”)	One of bidder has requested to amend the packaging type of this item from Alu-Alu to Alum. Strip.	Tender conditions prevail.

(2) The following Annexure-XV (Declaration towards Compliance of Order (Public Procurement No.1, 2 & 3) dated 23 Jul 2020& 24 Jul 2020 under Rule 144 (xi) of the General Financial Rules (GFRs), 2017) has been added as Sl. 23 in continuation to Sl. No. 22 in Annexure-I Checklist of the tender document.

S.N.	Check List	YES/No	Page No.	Remarks
23	Annexure XV (Clause No. 3. (1) Declaration towards Compliance of Order (Public Procurement No.1, 2 & 3) dated 23 Jul 2020& 24 Jul 2020 under Rule 144 (xi) of the General Financial Rules (GFRs), 2017 on Non-Judicial Paper duly notarized. Only copy shall be submitted to PMBI with technical bid cover-A.			

Part B: Declaration towards Compliance of Order (Public Procurement No.1, 2 & 3) dated 23 Jul 2020 & 24 Jul 2020 on Restrictions under Rule 144 (xi) of the General Financial Rules (GFRs), 2017 by Authorised Signatory of the Firm Shall Be Submitted as Per Below Format on Non-Judicial Paper duly notarized.

Format:

ANNEXURE- XV

(Ref. Clause no.3.1)
DECLARATION BY AUTHORISED SIGNATORY OF THE FIRM
(On Non-Judicial Paper duly notarized)

(Declaration towards Compliance of Order (Public Procurement No.1, 2 & 3) dated 23 Jul 2020 & 24 Jul 2020 on Restrictions under Rule 144 (xi) of the General Financial Rules (GFRs), 2017.)

I, the undersigned,..... (full names), do hereby declare, in my capacity as.....of M/s, that:

- 1) The facts contained herein are within my own personal knowledge.
- 2) I have read the Order (Public Procurement No.1, 2 & 3) dated 23 Jul 2020 & 24 Jul 2020 on the subject of Restrictions under Rule 144 (xi) of the General Financial Rules (GFRs), 2017 regarding restrictions on procurement from a bidder of a country which shares a land border with India and comply to all the provisions of the Order.
- 3) I certify that M/s(name of bidder/entity) is not from such a country or, is from such a country (strike out whichever is not applicable), has been registered with the Competent Authority. I hereby certify that this SUPPLIER fulfils all requirements in this regard and is eligible to be considered. [Where applicable, evidence of valid registration by the Competent Authority is attached].
- 4) I understand that the submission of incorrect data and / or if certificate / declaration given by M/s.....(name of bidder entity) is found to be false, this would be a ground for immediate termination and further legal action in accordance with law as per Clause 12 of the Public Order on Restrictions under Rule 144 (xi) of the General Financial Rules (GFRs), 2017.

Authorized Signature:

Signature with date.....

Name:

Designation/ capacity

(Seal / Stamp of Bidder)

All other contents of tender document remain unaltered. Bidders are requested to quote their rates considering all the terms and condition of the tender document including above clarification/amendment no. 1 dated 11/01/2022.

Sd/-
DGM (Procurement & Quality)
For & on behalf of PMBI
Ph: 011-49431811